Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873102 · ClinicalTrials.gov registry record · Phase 2
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
A Phase 2 study of Cirrhosis, Liver and Cytopenia, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04873102 is a Phase 2 study of Cirrhosis, Liver and Cytopenia that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 10 participants, below the 242-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04873102, a Phase 2 study of Cirrhosis, Liver and Cytopenia, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.
Conditions Studied
Interventions
- DRUG Danazol Pill
Study Locations (1)
California
- Keck Hosital of USC - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04873102
The ClinicalTrials.gov registry entry for NCT04873102 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (96% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 1 intervention - of which Danazol Pill is the first listed.
NCT04873102 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04873102 about?
NCT04873102 is a clinical study titled "Danazol for Treatment of Cytopenias in Patients With Cirrhosis". This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months...
What is the current status of trial NCT04873102?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2024-08-01. Estimated completion is 2027-08-01.
What conditions does trial NCT04873102 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Cytopenia.
What interventions are being tested in trial NCT04873102?
The interventions under investigation include: Danazol Pill (DRUG).
Who is sponsoring clinical trial NCT04873102?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873102 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
RECRUITING · Phase 2
-
EGCG for Hepatocellular Carcinoma Chemoprevention
RECRUITING · Phase 2
-
Liver Cancer Disparities in American Indian and Alaska Native Persons
RECRUITING · Phase 2
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.